Lorazepam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the evidence pack, I selected insomnia (rank 2, TxGNN score 99.80%, L1 evidence) rather than the top-ranked “trigeminal nerve neoplasm” as the primary predicted indication, because the evidence pack’s own rationale flags rank 1 as a likely knowledge-graph false positive with zero supporting trials or literature. Insomnia is the only candidate in this pack with a completed Phase 3 RCT, 23 registered trials, and 18 publications — the substantively decision-relevant signal. This deviation is noted explicitly below.
Lorazepam: From Anxiety Disorders to Insomnia
One-Sentence Summary
Lorazepam is a benzodiazepine (GABA-A receptor positive allosteric modulator) historically used for anxiety, sedation, and seizure control. The TxGNN model predicts it may be effective for Insomnia, with 23 clinical trials and 18 publications currently supporting this direction.
Note: The single highest-scoring TxGNN prediction in this evidence pack (“trigeminal nerve neoplasm”) was excluded from this report because it has zero clinical trials and zero literature, and the model’s own rationale identifies it as a probable embedding artifact/false positive with no plausible mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established in Canadian (Health Canada) regulatory records — the drug is not currently marketed in Canada. Classically used as an anxiolytic / sedative-hypnotic (benzodiazepine class), per the pharmacology stated in this evidence pack. |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L1 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action text was not returned for this drug (flagged as a High-severity data gap, DG002). However, the evidence pack’s own repurposing rationale confirms the working pharmacology: Lorazepam is a GABA-A receptor positive allosteric modulator, producing central nervous system depression, anxiolysis, and anticonvulsant effects — the well-established core pharmacology of the benzodiazepine class.
Lorazepam’s original therapeutic uses (anxiety, sedation, seizure control) and the predicted new indication (insomnia) share the same underlying mechanism: GABA-A potentiation produces sedative-hypnotic effects that induce and maintain sleep. This is not a speculative cross-disease inference — sedation/sleep induction is a direct, on-target pharmacological effect of the drug class, not an indirect or off-target mechanism. Benzodiazepines, including lorazepam specifically, have in fact been used clinically and studied for insomnia for decades (see literature from 1988 onward below), and a lorazepam-containing combination product (SM-1, with diphenhydramine and zolpidem) has been directly tested in Phase 2/3 trials for transient insomnia.
The main caveat is that benzodiazepine use for chronic insomnia is increasingly de-emphasized in guidelines due to tolerance, dependence, and withdrawal risk — several trials in this evidence pack (e.g., BE-SAFE, benzodiazepine cessation studies) reflect this shift toward reducing rather than expanding benzodiazepine use in sleep disorders, which should temper the strength of the “Go” signal despite the mechanistic plausibility.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03331042 | Phase 3 | Completed | 85 | Randomized, double-blind, 4-way crossover trial of SM-1 (diphenhydramine + zolpidem + lorazepam) vs. two comparator combinations and placebo in a phase-advance model of transient insomnia — direct efficacy/safety evidence. |
| NCT03338764 | Phase 3 | Withdrawn | 0 | Planned double-blind, placebo-controlled trial of SM-1 for transient insomnia in adults; withdrawn before enrollment, so contributes no outcome data. |
| NCT02671760 | Phase 2 | Completed | 39 | Single-dose pharmacodynamic study of SM-1 vs. comparator/placebo on total sleep time in a 5-hour phase-advance insomnia model. |
| NCT04396327 | Phase 2 | Not yet recruiting | 14 | Crossover pharmacodynamic study of SM-1 vs. diphenhydramine+lorazepam in a 3-hour phase-advance transient insomnia model. |
| NCT02648776 | N/A | Unknown | 1400 | Taiwanese prospective cohort assessing risk/benefit, usage patterns, and outcomes of hypnotics (including benzodiazepines) in elderly patients with sleep disorders. |
| NCT02135198 | Phase 1 | Completed | 12 | Crossover biomarker study of a GABA-A modulator (AZD7325) on cortical inhibition, providing class-level GABAergic pharmacodynamic support relevant to insomnia/sedation mechanisms. |
| NCT02530580 | Phase 1 | Completed | 12 | Crossover biomarker study of GABA-A modulator AZD7325 on cutaneous sensation, contextualizing benzodiazepine-class GABAergic effects and tolerability profile. |
(7 of 23 registered trials shown, prioritized for direct relevance to lorazepam and GABAergic hypnotic mechanisms; trials focused on benzodiazepine deprescribing/cessation or unrelated psychiatric indications were excluded as not supportive of this indication.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3280615 | 1988 | RCT | Journal of Clinical Pharmacology | Double-blind crossover trial in 8 chronic insomniacs: lorazepam 2 mg outperformed flurazepam 30 mg on most sleep parameters over 3 weeks. |
| 30625122 | 2018 | Review | The Medical Letter on Drugs and Therapeutics | Independent review of pharmacologic options for chronic insomnia, including benzodiazepines. |
| 10220122 | 1999 | Cohort | International Clinical Psychopharmacology | Evaluated lorazepam 0.5 mg TID vs. 1.5 mg HS in primary insomnia; TID dosing hypothesized to better address daytime fatigue symptoms. |
| 35087274 | 2022 | Review | Journal of Multidisciplinary Healthcare | Reviews efficacy, safety, and drug-drug interactions of insomnia therapies (“coronasomnia”) in COVID-19 patients. |
| 15341891 | 2004 | Cohort | Sleep Medicine | Analysis of hypnotic prescribing patterns (including benzodiazepines) in a large managed-care population. |
| 19514972 | 2009 | Preclinical | Drug Delivery | Developed a microemulsion-based intranasal delivery system for lorazepam (with diazepam and alprazolam) and demonstrated sleep-induction efficacy in a rat model. |
| 23330992 | 2013 | Review | Expert Opinion on Drug Metabolism & Toxicology | Reviews pharmacokinetics of anxiolytic drugs, the most widely prescribed psychoactive drug class, relevant to sedative-hypnotic dosing. |
| 36692463 | 2023 | Meta-analysis | Acta Pharmaceutica | Meta-analysis of tranquilizer use (dose, efficacy, adverse effects) in elderly patients with chronic non-communicable disease. |
| 41392764 | 2026 | RCT (preclinical) | Food & Function | Mouse-model RCT showing a probiotic strain ameliorates insomnia via GABA/serotonin signaling — supports the GABAergic mechanism relevant to insomnia broadly, though not lorazepam-specific. |
| 39315391 | 2024 | Cohort | BMJ Neurology Open | Characterizes benzodiazepine prescribing patterns, including for sleep-related complaints, in a US clinical population. |
Canada Market Information
Lorazepam currently has no active Health Canada market authorization under this evidence pack (market_status: 未上市 / Not Marketed, total_licenses: 0). No Drug Identification Numbers (DINs) or product listings are available to summarize.
Safety Considerations
Please refer to the Health Canada product monograph for safety information. No key warnings, contraindications, or drug-drug interaction data were returned in this evidence pack (all fields flagged as Data Gap DG001 — a Blocking-severity gap that prevents formal S1 safety pre-screening).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Insomnia has the strongest evidentiary support in this evidence pack — one completed Phase 3 RCT and several supporting Phase 1/2 trials directly testing a lorazepam-containing combination product, plus literature dating back to 1988 establishing lorazepam’s hypnotic efficacy — combined with a mechanistically direct (not speculative) link via GABA-A receptor potentiation. However, benzodiazepine-class dependence, tolerance, and withdrawal risks, the complete absence of safety/contraindication data (DG001, Blocking), and the lack of any current Canadian market authorization mean this cannot proceed as an unconditional “Go.”
To proceed, the following is needed:
- TFDA/Health Canada product monograph warnings, contraindications, and precautions (DG001 — Blocking, must be resolved before any S1 safety evaluation)
- Formal DrugBank-sourced mechanism-of-action documentation (DG002 — High priority)
- Drug-drug interaction data (current query status: not found)
- Clarification of regulatory pathway given zero current Canadian DINs (research-use classification vs. new submission)
- A dependence/withdrawal risk assessment specific to chronic (vs. transient) insomnia use, given benzodiazepines’ well-documented long-term safety concerns in this population
- Follow-up on NCT04396327 (not yet recruiting) and re-evaluation of why NCT03338764 (Phase 3) was withdrawn, as both affect confidence in the L1 evidence rating
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.